SCHEMBL30765495

SCHEMBL30765495

Cc1nc(-c2ccccc2)n(CC(=O)NCc2cc3cnccc3[nH]2)c(=O)c1N[C@H](C)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.36
CMA1 P23946 5/20 0.35
CTRC Q99895 4/20 0.35
NTRK1 P04629 2/20 0.35
ELANE P08246 4/20 0.35
F3 P13726 3/20 0.34
MAPK1 P28482 2/20 0.34
ALDH1A1 P00352 1/20 0.34
NTRK3 Q16288 1/20 0.34
AVPR1B P47901 1/20 0.33
F10 P00742 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765543 0.90 ELANE (0.39) F2CMA1CTRCNTRK1ELANE
SCHEMBL30765440 0.87 F7 (0.39) F2NTRK1ELANEF3MAPK1
SCHEMBL30765516 0.83 NTRK1 (0.35) F2CMA1CTRCNTRK1F3
SCHEMBL30765885 0.83 MAPK1 (0.34) F2CMA1CTRCNTRK1F3
SCHEMBL30766011 0.83 CMA1 (0.33) F2CMA1CTRCNTRK1ELANE
SCHEMBL30765642 0.83 MAPK1 (0.35) F2NTRK1ELANEF3MAPK1
SCHEMBL30765870 0.83 F2 (0.35) F2F3MAPK1ALDH1A1F10
SCHEMBL30765603 0.82 F2 (0.35) F2F3MAPK1ALDH1A1F10
SCHEMBL30765497 0.82 POLB (0.36) F2MAPK1ALDH1A1
SCHEMBL31558449 0.82 CYP1A2 (0.38) ELANEALDH1A1AVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed